4 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Oxurion: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Terminated | Oxurion | 16 | 2021-08-27 | 2023-08-18 |
| Retinal and Cognitive Dysfunction in Type 2 Diabetes Retinal Function, Cognitive Dysfunction | Completed | Hospital Universitari Vall d'Hebron Research Institute | 510 | 2020-11-16 | 2025-03-12 | |
| A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3 - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Completed | Oxurion | 135 | 2020-07-31 | 2023-11-27 |
| A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) Ranibizumab 0.5mg, THR-317 8mg, Sham injection - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Completed | Oxurion | 70 | 2018-04-20 | 2019-08-02 |
| Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours TB-403 - Solid Tumors | Phase 1 | Completed | BioInvent International AB | 21 | 2008-06-01 | 2022-03-16 |
Diabetes Mellitus (3) · Diabetic Retinopathy (3) · Cognitive Dysfunction (1) · Macular Edema (1)
TB-403 (2) · aflibercept (2) · Ranibizumab (1) · salicylhydroxamic acid (1)
Spain (3) · France (2) · Germany (2) · Slovakia (2) · United Kingdom (2) · United States (2) · Belgium (1) · Czechia (1) · Denmark (1) · Estonia (1) · Hungary (1) · Italy (1) · Latvia (1) · Lithuania (1) · Switzerland (1)
Dorthe Nielsen, MD, PhD (1) · Lena Winstedt, PhD (1) · Noemi Lois, Prof. (1) · Ulrik Lassen, MD, PhD (1)
2017 (1), 2019 (1)